ZyVersa Therapeutics, Inc. ZVSA
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.79M | -678.60K | -19.81M | -2.21M | -2.26M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | 57.20K | -- | -- | -- |
| Total Other Non-Cash Items | 412.00K | 17.40K | 17.90M | 188.00K | 153.90K |
| Change in Net Operating Assets | 582.20K | 190.30K | 498.80K | 501.60K | 331.00K |
| Cash from Operations | -799.10K | -413.70K | -1.41M | -1.52M | -1.77M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 1.00M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 2.05M | 200.00 | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -12.50K | -189.00K | -17.90K | 1.85M |
| Cash from Financing | 1.00M | -12.50K | 1.86M | -17.70K | 1.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 200.90K | -426.20K | 455.90K | -1.54M | 80.60K |